Want to see ELTX full AI Analyst Report?
ELTX Stock Chart & Stats
$3.01
$0.02(0.67%)
At close: 4:00 PM EDT
$3.01
$0.02(0.67%)
Day’s Range― - ―
52-Week Range$1.55 - $16.00
Previous CloseN/A
Volume163.39K
Average Volume (3M)313.68K
Market Cap
$42.26M
Enterprise Value$65.91M
Total Cash (Recent Filing)$23.48M
Total Debt (Recent Filing)$14.15M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding27,091,187
10 Day Avg. Volume244,435
30 Day Avg. Volume313,675
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market Cap1.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-228.08
Enterprise Value/Ebitda-1.64
Forecast
1Y Price Target
$15.50Price Target Upside414.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.89
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Immunotherapy PlatformElicio’s AMP platform provides a defined technological approach to enhancing tumor-specific T-cell responses by directing immune-stimulating agents and antigens to lymph nodes. If clinical validation continues, this platform could support multiple oncology programs rather than a single-product opportunity.
Losses ModeratingThe reduction in annual net losses indicates some improvement from the 2024 trough, which may help extend financial flexibility if the trend continues. However, losses remain substantial, so this is a modest positive rather than evidence of approaching profitability or operating leverage.
Clinical And Funding SupportRecent financing provides additional resources for advancing clinical programs, while reported complete responses in select patients offer supportive signals for the broader immunotherapy strategy. Together, these developments can help preserve development momentum, although they do not remove clinical or dilution risk.
Bears Say
No Commercial RevenueThe absence of revenue confirms that Elicio remains entirely dependent on clinical development and external capital rather than an established commercial franchise. Without product sales, future financial progress depends on successful trials, regulatory advancement, and eventual commercialization of its pipeline.
Persistent Cash BurnPersistent cash consumption near $38 million annually places continuing pressure on liquidity and makes outside financing an ongoing requirement. This can constrain development choices, increase dilution exposure, and leave the company financially vulnerable if clinical milestones or fundraising conditions do not develop as planned.
Phase 2 Efficacy SetbackMissing the primary endpoint is a material validation setback because it weakens confidence that the lead clinical strategy can produce reliable efficacy in the intended population. Post-hoc subgroup findings and a refined Phase 3 plan may help, but they do not replace prospective primary-endpoint success.
Elicio Therapeutics News
ELTX FAQ
What was Elicio Therapeutics’s price range in the past 12 months?
Elicio Therapeutics lowest stock price was $1.55 and its highest was $16.00 in the past 12 months.
What is Elicio Therapeutics’s market cap?
Elicio Therapeutics’s market cap is $42.26M.
When is Elicio Therapeutics’s upcoming earnings report date?
Elicio Therapeutics’s upcoming earnings report date is Mar 26, 2027 which is in 158 days.
How were Elicio Therapeutics’s earnings last quarter?
Elicio Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.538 by $0.108.
Is Elicio Therapeutics overvalued?
According to Wall Street analysts Elicio Therapeutics’s price is currently Undervalued.
Does Elicio Therapeutics pay dividends?
Elicio Therapeutics does not currently pay dividends.
What is Elicio Therapeutics’s EPS estimate?
Elicio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elicio Therapeutics have?
Elicio Therapeutics has 27,091,187 shares outstanding.
What happened to Elicio Therapeutics’s price movement after its last earnings report?
Elicio Therapeutics reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.538. Following the earnings report the stock price went down -1.905%.
Which hedge fund is a major shareholder of Elicio Therapeutics?
Currently, no hedge funds are holding shares in ELTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elicio Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (414.95% Upside)
$15.50 (414.95% Upside)
Blogger Sentiment
Neutral
ELTX Sentiment 50%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.47%
12-Months-Change
Fundamentals
Return on Equity
-1266.43%
Trailing 12-Months
Asset Growth
6.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Elicio Therapeutics
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
ELTX Stock 12 Month Forecast
Average Price Target
$15.50
▲(414.95% Upside)
Technical Analysis
Compugen
―
―
Seres Therapeutics
―
Milestone Pharmaceuticals
―
Actuate Therapeutics, Inc.
―
Ownership Overview
21.52% Insiders
2.32% Mutual Funds
4.65% Other Institutional Investors
67.15% Public Companies and
Individual Investors